Jedd D. Wolchok
Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.
Overview
Jedd Wolchok (Weill Cornell Medicine; formerly MSKCC) was principal investigator of CheckMate 067, which established nivolumab plus ipilimumab as the most durable therapy in advanced melanoma with median survival beyond six years and ten-year melanoma-specific survival near 50%. He led early ipilimumab development, defined the immune-related response criteria, and co-founded the Parker Institute network. His laboratory studies mechanisms of checkpoint blockade.
Before 2011 median survival in metastatic melanoma was under a year; this trial shows that roughly half of patients treated with combination checkpoint blockade are now long-term survivors, effectively cured. It anchors first-line treatment of advanced melanoma and sets the benchmark for every new regimen, including nivolumab-relatlimab. The combination's toxicity means nivolumab alone or newer doublets remain reasonable for some patients.
This paper launched the immunotherapy era. It was the first randomised evidence that taking a brake off the immune system could extend life in a solid cancer, and it introduced clinicians to immune-related adverse events and to responses that arrive late or after apparent progression. Ipilimumab alone has since been superseded by PD-1 antibodies and combinations, but every checkpoint programme traces back to this result.
Pages like this
not linked directly; found by shared links- PersonMichael A. Postow
Shares CheckMate 067, CTLA-4, Ipilimumab, Nivolumab and the tags melanoma, immunotherapy.
- PersonCaroline Robert
Shares Ipilimumab, Nivolumab, PD-1, Melanoma and the tags melanoma, immunotherapy, trialist.
- PersonF. Stephen Hodi
Shares CheckMate 067, Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma, CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later, CTLA-4.
- PersonPaolo A. Ascierto
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
- PersonPaul Baas
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
- PersonHeinz-Josef Lenz
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
- PersonGeorgina V. Long
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
- PersonJennifer A. Wargo
Shares Ipilimumab, Nivolumab, Melanoma, Immune checkpoint inhibitors and the tag melanoma.